Because of several reasons, the current analyst projected EPS numbers for 2012 and 2013 are understated IMO.
IMO a guess at 2012 EPS would be $0.28 (perhaps higher).
IMO a guess at 2013 EPS would be $0.42 (perhaps higher).
IMO a guess at 2013 EPS would be $0.52 (perhaps higher).
The EPS improvement will likely occur because of several reasons: 1) lower legal fees; 2) slowly growing tissue sales coupled with slowly growing tissue margin improvement; 3) growing BioGlue sales; Even the high EPS analyst number is presently understated IMO. Increasing EPS going forward is the main reason to own the stock. The improvement comes mainly from lower legal fees and improving BioGlue sales.
All a bunch of fluff. KISS Keep it simple stupid, this applies to today's market. The only thing that matters in trading is what the Commodore 64 computer thinks that is running the NYSE and Naz trading. People of intellect are gone and not coming back that in the past bought stocks.